Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer

Lisha Wang, Fei Ren, Qifeng Wang, Lee Ann Baldridge, M. Francesca Monn, Kurt W. Fisher, Weiqi Sheng, Xiaoyan Zhou, Xiang du, Liang Cheng

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results: In univariate analysis, TNM stage (p <0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 95 % CI 1.51–4.12, p <0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalMolecular Diagnosis and Therapy
DOIs
StateAccepted/In press - Feb 18 2016

Fingerprint

Colorectal Neoplasms
Ligands
Neoplasms
Clinical Protocols
Immunotherapy
Multivariate Analysis
Survival

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

Cite this

Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. / Wang, Lisha; Ren, Fei; Wang, Qifeng; Baldridge, Lee Ann; Monn, M. Francesca; Fisher, Kurt W.; Sheng, Weiqi; Zhou, Xiaoyan; du, Xiang; Cheng, Liang.

In: Molecular Diagnosis and Therapy, 18.02.2016, p. 1-7.

Research output: Contribution to journalArticle

Wang, Lisha ; Ren, Fei ; Wang, Qifeng ; Baldridge, Lee Ann ; Monn, M. Francesca ; Fisher, Kurt W. ; Sheng, Weiqi ; Zhou, Xiaoyan ; du, Xiang ; Cheng, Liang. / Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. In: Molecular Diagnosis and Therapy. 2016 ; pp. 1-7.
@article{e177f2e88c044172b139e6455e11d3e0,
title = "Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer",
abstract = "Introduction: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results: In univariate analysis, TNM stage (p <0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 {\%} CI 1.09–3.05, p = 0.021; HR 2.49, 95 {\%} CI 1.51–4.12, p <0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.",
author = "Lisha Wang and Fei Ren and Qifeng Wang and Baldridge, {Lee Ann} and Monn, {M. Francesca} and Fisher, {Kurt W.} and Weiqi Sheng and Xiaoyan Zhou and Xiang du and Liang Cheng",
year = "2016",
month = "2",
day = "18",
doi = "10.1007/s40291-016-0188-1",
language = "English (US)",
pages = "1--7",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer

AU - Wang, Lisha

AU - Ren, Fei

AU - Wang, Qifeng

AU - Baldridge, Lee Ann

AU - Monn, M. Francesca

AU - Fisher, Kurt W.

AU - Sheng, Weiqi

AU - Zhou, Xiaoyan

AU - du, Xiang

AU - Cheng, Liang

PY - 2016/2/18

Y1 - 2016/2/18

N2 - Introduction: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results: In univariate analysis, TNM stage (p <0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 95 % CI 1.51–4.12, p <0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.

AB - Introduction: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results: In univariate analysis, TNM stage (p <0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 95 % CI 1.51–4.12, p <0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84958739399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958739399&partnerID=8YFLogxK

U2 - 10.1007/s40291-016-0188-1

DO - 10.1007/s40291-016-0188-1

M3 - Article

SP - 1

EP - 7

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

ER -